Improving Therapy Adherence Cost-Effectively with Measurable Impact
A UK Case Study in Diabetes
At a time when chronic, long-term conditions threaten to engulf the NHS, medicines optimisation is at the forefront of strategies to help stakeholders across the healthcare spectrum obtain the maximum value from investment in and use of medicines. Adherence to therapy is a critical enabler in this process, requiring multidisciplinary efforts to encourage better patient understanding and ownership of their treatment.
This new IQVIA white paper provides key recommendations for:
- Manufacturers to take a lead in implementing simple, scalable solution
- Health system processes to turn data and analytics into actionable insights and to monitor progress
- Options to significantly impact adherence, disease burden and patient outcomes